Hemostemix Inc · TSXV:HEM
Hemostemix — Investor Presentation (March 2022)
18 slides from Hemostemix's investor presentation, Mar 29, 2022
Slide 1: Hemostemix: Your Fountain of Youth - Investor Presentation
Hemostemix: Your Fountain of Youth TM Investor Presentation © Hemostemix Inc. All rights reserved. Jan-Feb 2022 Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) © Hemostemix Inc. All rights reserved.
Slide 2: Forward-Looking Information
FORWARD-LOOKING INFORMATION This presentation contains forward looking statements that reflect management’s expectations regarding the future growth and results of operational performance including but not limited to the scientific, financial, competitive and business prospects of Hemostemix Inc. (“
Slide 3: The Problems we Solve – Demonstrated by 500 Treatments
The Problems we Solve – Demonstrated by 500 Treatments ISCHEMIC CARDIOMYOPATHY AND CLI IMPROVEMENTS 47 Days post ACP-01 Before Treatment After Clink on the left picture to watch the echo cardiogram, results of ACP treatment 3
Slide 4: Our Business Model and Vision
Our Business Model and Vision Leveraging your stem cells to Regain or Maintain your Quality of Life is the Gold Standard of Health At $5,000 per Treatment ($2,500 COGS) Hemostemix scales to 4,000 shipments per month, to become the #1 Provider in the fresh autologous Stem Cell space. Leveraging the S
Slide 5: Experienced Senior Leadership Team & International Advisors
HEMOSTEMIX EXPERIENCED SENIOR LEADERSHIP TEAM & INTERNATIONAL ADVISORS Management and Directors Advisory Board Thomas Smeenk, BA Timothy Chang, BA President & CEO, Co-Founder & Director Private Investor and an investment committee member of an Asian- Christina Wu, CPA, CGA based hedge fund with aver
Slide 6: Hemostemix Overview
HEMOSTEMIX - OVERVIEW Global IP Portfolio Pursuing Key Strategic Partnerships 91 Patents issued Worldwide U of A 5 patent families including automation of NCPCo production CCPCo Expandable Technology Platform Data Driven Biotech Company ACP-01 – 5 indications Historical Data >500 patients treated NC
Slide 7: ACP-01 Clinical Experience
TRIAL HISTORY ACP-01 CLINICAL EXPERIENCE TYPE OF Clinical Trial Pilot Safety/ Phase 1b Safety Phase 2 Safety Safety/ Safety and Safety and STUDY Feasibility and Efficacy and Efficacy Feasibility Efficacy Efficacy STUDY Thailand Hungary Canada and United States Thailand Thailand Bangkok Heart LOCATIO
Slide 8: Clinical Development Strong Pipeline
CLINICAL DEVELOPMENT STRONG PIPELINE Candidate Indication Preclinical Phase I Phase 2 Status ACP-01 + U of A Islet Cells Lead Clinical-Stage Type 1 Diabetes Product Candidate ACP-01 Critical Limb Ischemia PAD Angina Pectoris Safety Trials Ischemic Cardiomyopathy COMPLETED in Dilated Cardiomyopathy M
Slide 9: Phase 2 CLI Trial Milestones
PHASE 2 CLI TRIAL MILESTONES H2 2017 H1 2018 H2 2018 H1 2019 H2 2019 H2 2020 2022 Phase 2 CLI Trial CRO engaged Health Canada Approval¹ US FDA Approval² Site & Patient Recruiting First Patient Treatment³ Patient Monitoring Study Completion⁴ A catalyst for future trials Progression of the CLI Trial h
Slide 10: ACP-01 Process
ACP-01 PROCESS 2 Isolation of SCP 1 Blood collection and shipping Blood collection 1 and shipping Culturing and 2 Isolation of SCP differentiation 3 of cells 3 Culturing and differentiation of cells 4 Cell harvesting Quality Control release tests 5 and batch qualification Cell harvesting 4 6 Packagi
Slide 11: What's Unique About Scalable Autologous ACP-01? Key Differentiators
WHAT’S UNIQUE ABOUT SCALABLE AUTOLOGOUS ACP-01? KEY DIFFERENTIATORS Autologous. Proven safety Blood draw: safer, less invasive Global portfolio of 91 patents and efficacy than fat or bone marrow Including automated production Non-surgical, enhanced cell therapy treatment for restoring circulation to
Slide 12: Share Capital & Offering Overview
SHARE CAPITAL & OFFERING OVERVIEW Share capital structure as of Mar 31, 2022 ($CAD) Number Ex. Price Expiry or Closing Common Shares Issued and Outstanding 69,199,657 Stock Options 6,775,694 $0.17 - $2.00 Apr 2023-Mar 2027 Share Purchase Warrants 50,574,383 $0.40 - $1.00 Mar 2023-Feb 2024 Broker War
Slide 13: Hemostemix – Proforma Org. Chart
HEMOSTEMIX – Proforma Org. Chart Hemostemix IP Hold Co. Kwalata Trading Limited Central & Peripheral U of A Agreement Heart Co. Nervous System Type 1 Diabetes All Cardiovascular PreCerv Inc. 13
Slide 14: Hemostemix – Use of Proceeds
HEMOSTEMIX – Use of Proceeds ❑ ACP-01 ❑ Finalize Phase II study ❑ Transfer ACP to Univ of Alberta, Edmonton, to combine with Islet cells - Type 1 Diabetes ❑ Start automation of production ❑ NCP-01 ❑ Transfer NCP to Clemson Univ. to complete spinal cord injury study ❑ Business development including l
Slide 15: Operations Forecast
HEMOSTEMIX Operations Forecast A phased approach to Batch Cost Reduction and Profitability 15
Slide 16: Operations Forecast
HEMOSTEMIX Operations Forecast A phased approach to Batch Cost Reduction and Profitability 16
Slide 17: Operations Forecast
HEMOSTEMIX Operations Forecast A phased approach to Batch Cost Reduction and Profitability 17
Slide 18: Hemostemix – Why Invest Now?
HEMOSTEMIX – Why Invest Now? ❑ Very favorable valuation ❑ ACP as a therapeutic: ❑ Six published studies of ACP’s safety and efficacy ❑ 500 treatments demonstrating success as a compassionate therapeutic of Ischemic Cardiomyopathy and Angina, CLI, PAD, COPD, Idiopathic Pulmonary Hypertension, Vascula